康辰药业(603590.SH)：KC1086完成I期临床试验首例受试者入组

Core Viewpoint - Kangchen Pharmaceutical (603590.SH) has successfully completed the enrollment of the first subject in the Phase I clinical study (KC1086-I-01) evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of KC1086 for the treatment of advanced recurrent or metastatic solid tumors [1] Group 1 - KC1086 is a small molecule inhibitor with a novel structure that selectively targets Lysine Acetyltransferase 6 (KAT6) [1] - The drug is entirely developed by Beijing Kangchen Pharmaceutical Co., Ltd. [1] - The clinical study aims to assess the drug's potential in treating advanced recurrent or metastatic solid tumors [1]